8-K: Kymera Reports Q4/FY25 Results, Advances Pipeline, Boosts Cash

Kymera Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting pipeline progress for its STAT6 and IRF5 degrader programs and a strong cash position.

Summary

• Collaboration revenues were $2.9 million for Q4 2025 and $39.2 million for FY 2025, down from $7.4 million and $47.1 million respectively in 2024.
• Research and development expenses increased to $83.8 million for Q4 2025 and $316.6 million for FY 2025, up from $71.8 million and $240.2 million respectively in 2024.
• Net loss was $87.0 million for Q4 2025 and $311.4 million for FY 2025, compared to $70.8 million and $223.9 million respectively in 2024.
• Kymera Therapeutics held $1.6 billion in cash, cash equivalents, and investments as of December 31, 2025, extending its cash runway into 2029.
• The KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) is ongoing, with data expected by mid-2027.
• The KT-621 BREADTH Phase 2b trial in asthma is ongoing, with data expected in late-2027.
• Dosing was initiated in the KT-579 (IRF5) Phase 1 healthy volunteer trial, with data expected in the second half of 2026.
• Dr. Neil Graham was appointed as Chief Development Officer.
• The company completed a $602 million underwritten equity offering in December 2025, with total gross proceeds of approximately $692 million including the overallotment option.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, primarily driven by significant pipeline advancements, positive clinical data for KT-621, and a substantially strengthened financial position with an extended cash runway, despite increased operating losses typical for a growth-stage biotech.

Positives

• Strong cash position of $1.6 billion as of December 31, 2025, providing a cash runway into 2029.
• KT-621 BROADEN2 Phase 2b trial in atopic dermatitis expanded to include adolescents.
• KT-621 BREADTH Phase 2b trial in asthma commenced dosing.
• KT-621 completed GLP chronic toxicology studies with no adverse findings across all doses and concentrations tested.
• Positive results from the KT-621 BroADen Phase 1b clinical trial in moderate to severe AD patients, demonstrating deep STAT6 degradation, robust reductions in Type 2 inflammatory biomarkers, and meaningful improvements in clinical endpoints.
• KT-621 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of moderate to severe AD.
• Initiated dosing in the first-in-human KT-579 Phase 1 healthy volunteer trial.
• Preclinical studies for KT-579 showed activity equal to or more efficacious than small molecule inhibitors and biologics currently marketed or in the clinic for lupus and rheumatoid arthritis, with no adverse effects in safety studies.
• Appointment of Dr. Neil Graham as Chief Development Officer, bringing over 30 years of global biopharma leadership experience.
• Successful completion of a $602 million underwritten equity offering in December 2025, with total gross proceeds of approximately $692 million.

Negatives

• Collaboration revenues decreased to $2.9 million in Q4 2025 from $7.4 million in Q4 2024, and to $39.2 million for FY 2025 from $47.1 million for FY 2024.
• Research and development expenses increased to $83.8 million in Q4 2025 from $71.8 million in Q4 2024, and to $316.6 million for FY 2025 from $240.2 million for FY 2024.
• Net loss increased to $87.0 million in Q4 2025 from $70.8 million in Q4 2024, and to $311.4 million for FY 2025 from $223.9 million for FY 2024.

Risks

• Cross-trial comparisons may not be reliable as no head-to-head trials have been conducted comparing KT-621 to dupilumab, and Phase 1 clinical data for KT-621 may not be directly comparable to dupilumab's clinical data due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics.
• Preclinical and clinical data, including the results from the Phase 1 trials of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate.
• Uncertainties inherent in the initiation, timing, and design of future clinical trials.
• The availability and timing of data from ongoing and future clinical trials and the results of such trials.
• The ability to successfully demonstrate the safety and efficacy of drug candidates.
• The timing and outcome of planned interactions with and submissions to regulatory authorities.
• The availability of funding sufficient for operating expenses and capital expenditure requirements.
• The unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development.

Future Outlook

Kymera Therapeutics expects its cash balance of $1.6 billion to provide a runway into 2029, extending beyond multiple clinical inflection points. The company anticipates reporting data from the KT-579 Phase 1 trial in the second half of 2026, data from the KT-621 BROADEN2 Phase 2b trial by mid-2027, and data from the KT-621 BREADTH Phase 2b trial in late-2027. Clinical entry for the partnered KT-485/SAR447971 program is expected in 2026, and the company plans to advance at least one new development candidate towards IND in 2026.

Management Comments

• "We set a high bar for what we wanted to achieve in 2025 and exceeded expectations. We enter this year with momentum and focus as we continue to advance an innovative and robust pipeline, anchored by our STAT6 program." Nello Mainolfi, PhD, Founder, President and CEO.
• "Across many immuno-inflammatory diseases, patients face tradeoffs, often compromising on efficacy, safety, or convenience. We see an opportunity to change the status quo." Nello Mainolfi, PhD.
• "With highly encouraging Phase 1b data in atopic dermatitis demonstrating consistent impact across every measure evaluated, and two parallel Phase 2b studies now underway in atopic dermatitis and asthma, KT-621 highlights the opportunity to meaningfully expand the reach to patients who need and deserve treatment, move therapy earlier in the disease journey, and ultimately improve outcomes for millions of patients." Nello Mainolfi, PhD.
• "We also initiated dosing in the first-in-human Phase 1 healthy volunteer trial for KT-579, the first IRF5-directed mechanism to enter the clinic and a completely novel oral approach to addressing key drivers of multiple debilitating autoimmune conditions." Nello Mainolfi, PhD.
• "Additionally, with our highly productive small molecule discovery engine, we're poised to share at least one new high-value program later this year. All these exciting milestones underscore our momentum and commitment to transforming how common, lifelong immunological diseases are treated." Nello Mainolfi, PhD.

Industry Context

StockSavvy.ai notes that Kymera Therapeutics is a key player in the emerging field of targeted protein degradation (TPD), aiming to develop oral small molecule degraders for immunological diseases. This approach offers a novel mechanism to address targets previously inaccessible with conventional therapeutics, potentially disrupting the market for chronic inflammatory conditions like atopic dermatitis and asthma, which are currently dominated by biologics such as dupilumab. The company's focus on first-in-class mechanisms like STAT6 and IRF5 degraders positions it at the forefront of innovation in immunology.

Comparison to Industry Standards

• KT-621's impact on biomarkers and clinical endpoints in the Phase 1b AD trial was in line or numerically exceeded data reported from dupilumab studies after 4 weeks of treatment.
• Preclinical studies for KT-579 demonstrated activity equal to or more efficacious than small molecule inhibitors and biologics currently marketed or in the clinic for lupus and rheumatoid arthritis.
• The filing explicitly states that cross-trial comparisons may not be reliable as no head-to-head trials have been conducted comparing KT-621 to dupilumab, and Phase 1 clinical data for KT-621 may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics.

Management Changes

Stakeholder Impact

• Shareholders: The successful equity offering and extended cash runway provide financial stability and reduce immediate dilution risk, while pipeline progress offers potential for future value creation. Increased net losses reflect ongoing investment in R&D.
• Patients: Advancement of KT-621 and KT-579 programs offers potential new oral treatment options for a range of immunological diseases, including atopic dermatitis, asthma, lupus, and rheumatoid arthritis, with the potential for improved efficacy, safety, and convenience.
• Employees: Continued growth in the research and development organization and the appointment of a new Chief Development Officer indicate ongoing investment in human capital and a stable outlook for the company's workforce.
• Partners (Sanofi, Gilead Sciences): Continued preclinical activities for partnered programs (KT-485/SAR447971 with Sanofi, CDK2 degrader with Gilead) indicate ongoing collaboration and potential for future milestones or option exercise payments.

Next Steps

• Complete enrollment for KT-621 BROADEN2 Phase 2b trial in 2026.
• Report data from KT-579 Phase 1 healthy volunteer trial in 2H26.
• Clinical entry for KT-485/SAR447971 expected in 2026.
• Advance at least one new development candidate towards IND for a first-in-class, oral program in 2026.
• Report data from KT-621 BROADEN2 Phase 2b trial in AD by mid-2027.
• Report data from KT-621 BREADTH Phase 2b trial in asthma in late-2027.

Key Dates

Recommendation

The company has demonstrated strong execution on its clinical pipeline, with KT-621 showing promising Phase 1b data, receiving Fast Track designation, and progressing into two Phase 2b trials. The initiation of the KT-579 Phase 1 trial further diversifies its pipeline. Critically, the successful $692 million equity offering has significantly bolstered its cash position to $1.6 billion, extending its runway into 2029, which de-risks its operations through multiple key clinical readouts. While net losses increased, this is expected for a clinical-stage biotech investing heavily in R&D. The combination of strong clinical progress and robust financial health makes Kymera Therapeutics an attractive investment for long-term growth in the targeted protein degradation space.

Keywords

Kymera Therapeutics, KYMR, biopharmaceutical, targeted protein degradation, STAT6 degrader, KT-621, atopic dermatitis, asthma, IRF5 degrader, KT-579, lupus, rheumatoid arthritis, clinical trials, Phase 2b, Phase 1, financial results, cash runway, equity offering, immunological diseases, Type 2 inflammation, Sanofi, Gilead Sciences, CDK2 degrader, drug development, biotech, SEC filing, 8-K